Name | Number of supported studies | Average coverage | |
---|---|---|---|
type I pneumocyte | 10 studies | 31% ± 10% | |
endothelial cell | 8 studies | 22% ± 4% | |
type II pneumocyte | 6 studies | 26% ± 8% | |
adipocyte | 6 studies | 37% ± 24% | |
epithelial cell | 5 studies | 38% ± 11% | |
fibroblast | 5 studies | 21% ± 3% | |
basal cell | 5 studies | 22% ± 4% | |
macrophage | 4 studies | 17% ± 2% | |
astrocyte | 4 studies | 21% ± 8% | |
non-classical monocyte | 3 studies | 23% ± 5% | |
ciliated cell | 3 studies | 21% ± 4% | |
hepatocyte | 3 studies | 41% ± 23% | |
glutamatergic neuron | 3 studies | 34% ± 15% | |
club cell | 3 studies | 21% ± 3% | |
interneuron | 3 studies | 29% ± 13% | |
erythroblast | 3 studies | 35% ± 8% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
stomach | 100% | 1357.13 | 358 / 359 | 99% | 17.75 | 284 / 286 |
esophagus | 99% | 791.78 | 1437 / 1445 | 99% | 19.36 | 181 / 183 |
intestine | 99% | 1118.71 | 961 / 966 | 98% | 12.73 | 517 / 527 |
lung | 100% | 1273.92 | 577 / 578 | 97% | 13.79 | 1125 / 1155 |
ovary | 99% | 611.87 | 179 / 180 | 97% | 13.15 | 415 / 430 |
kidney | 100% | 925.35 | 89 / 89 | 94% | 17.82 | 848 / 901 |
breast | 100% | 1261.80 | 459 / 459 | 94% | 12.69 | 1050 / 1118 |
prostate | 100% | 876.21 | 245 / 245 | 93% | 18.86 | 467 / 502 |
pancreas | 100% | 896.32 | 328 / 328 | 92% | 8.92 | 164 / 178 |
skin | 100% | 865.19 | 1808 / 1809 | 92% | 7.18 | 434 / 472 |
bladder | 100% | 1019.62 | 21 / 21 | 91% | 11.55 | 459 / 504 |
thymus | 100% | 957.10 | 652 / 653 | 85% | 7.35 | 514 / 605 |
uterus | 99% | 617.41 | 169 / 170 | 82% | 7.82 | 375 / 459 |
liver | 100% | 1306.18 | 225 / 226 | 80% | 9.50 | 323 / 406 |
adrenal gland | 100% | 1649.18 | 258 / 258 | 68% | 4.69 | 156 / 230 |
brain | 62% | 238.79 | 1626 / 2642 | 91% | 6.55 | 640 / 705 |
adipose | 100% | 1139.43 | 1204 / 1204 | 0% | 0 | 0 / 0 |
muscle | 100% | 965.35 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 568.15 | 241 / 241 | 0% | 0 | 0 / 0 |
blood vessel | 99% | 629.59 | 1321 / 1335 | 0% | 0 | 0 / 0 |
peripheral blood | 96% | 842.47 | 894 / 929 | 0% | 0 | 0 / 0 |
heart | 89% | 567.96 | 764 / 861 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 87% | 10.06 | 39 / 45 |
eye | 0% | 0 | 0 / 0 | 84% | 4.58 | 67 / 80 |
lymph node | 0% | 0 | 0 / 0 | 59% | 4.61 | 17 / 29 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0036335 | Biological process | intestinal stem cell homeostasis |
GO_0036150 | Biological process | phosphatidylserine acyl-chain remodeling |
GO_0036151 | Biological process | phosphatidylcholine acyl-chain remodeling |
GO_1905885 | Biological process | positive regulation of triglyceride transport |
GO_0090158 | Biological process | endoplasmic reticulum membrane organization |
GO_0006656 | Biological process | phosphatidylcholine biosynthetic process |
GO_0034379 | Biological process | very-low-density lipoprotein particle assembly |
GO_1903573 | Biological process | negative regulation of response to endoplasmic reticulum stress |
GO_0036152 | Biological process | phosphatidylethanolamine acyl-chain remodeling |
GO_0045797 | Biological process | positive regulation of intestinal cholesterol absorption |
GO_0050728 | Biological process | negative regulation of inflammatory response |
GO_0030258 | Biological process | lipid modification |
GO_0045540 | Biological process | regulation of cholesterol biosynthetic process |
GO_0034378 | Biological process | chylomicron assembly |
GO_0016020 | Cellular component | membrane |
GO_0005789 | Cellular component | endoplasmic reticulum membrane |
GO_0003841 | Molecular function | 1-acylglycerol-3-phosphate O-acyltransferase activity |
GO_0071617 | Molecular function | lysophospholipid acyltransferase activity |
GO_0106263 | Molecular function | 1-acylglycerophosphoserine O-acyltransferase activity |
GO_0106262 | Molecular function | 1-acylglycerophosphoethanolamine O-acyltransferase activity |
GO_0047144 | Molecular function | 2-acylglycerol-3-phosphate O-acyltransferase activity |
GO_0047184 | Molecular function | 1-acylglycerophosphocholine O-acyltransferase activity |
Gene name | LPCAT3 |
Protein name | Lysophosphatidylcholine acyltransferase 3 Lysophospholipid acyltransferase 5 (EC 2.3.1.23) (EC 2.3.1.n6) Lysophospholipid acyltransferase 5 (LPLAT 5) (EC 2.3.1.-) (1-acylglycerophosphocholine O-acyltransferase) (EC 2.3.1.23) (1-acylglycerophosphoethanolamine O-acyltransferase) (EC 2.3.1.n7) (1-acylglycerophosphoserine O-acyltransferase) (EC 2.3.1.n6) (Lysophosphatidylcholine acyltransferase) (LPCAT) (Lyso-PC acyltransferase) (Lysophosphatidylcholine acyltransferase 3) (Lyso-PC acyltransferase 3) (Lysophosphatidylserine acyltransferase) (LPSAT) (Lyso-PS acyltransferase) (Membrane-bound O-acyltransferase domain-containing protein 5) (O-acyltransferase domain-containing protein 5) Lysophosphatidylcholine acyltransferase 3 (cDNA FLJ59910, highly similar to Membrane bound O-acyltransferase domain-containing protein 5) |
Synonyms | OACT5 MBOAT5 |
Description | FUNCTION: Lysophospholipid O-acyltransferase (LPLAT) that catalyzes the reacylation step of the phospholipid remodeling process also known as the Lands cycle . Catalyzes transfer of the fatty acyl chain from fatty acyl-CoA to 1-acyl lysophospholipid to form various classes of phospholipids. Converts 1-acyl lysophosphatidylcholine (LPC) into phosphatidylcholine (PC) (LPCAT activity), 1-acyl lysophosphatidylserine (LPS) into phosphatidylserine (PS) (LPSAT activity) and 1-acyl lysophosphatidylethanolamine (LPE) into phosphatidylethanolamine (PE) (LPEAT activity) . Favors polyunsaturated fatty acyl-CoAs as acyl donors compared to saturated fatty acyl-CoAs . Has higher activity for LPC acyl acceptors compared to LPEs and LPSs. Can also transfer the fatty acyl chain from fatty acyl-CoA to 1-O-alkyl lysophospholipid or 1-O-alkenyl lysophospholipid with lower efficiency (By similarity). Acts as a major LPC O-acyltransferase in liver and intestine. As a component of the liver X receptor/NR1H3 or NR1H2 signaling pathway, mainly catalyzes the incorporation of arachidonate into PCs of endoplasmic reticulum (ER) membranes, increasing membrane dynamics and enabling triacylglycerols transfer to nascent very low-density lipoprotein (VLDL) particles. Promotes processing of sterol regulatory protein SREBF1 in hepatocytes, likely by facilitating the translocation of SREBF1-SCAP complex from ER to the Golgi apparatus (By similarity). Participates in mechanisms by which the liver X receptor/NR1H3 or NR1H2 signaling pathway counteracts lipid-induced ER stress response and inflammation. Down-regulates hepatic inflammation by limiting arachidonic acid availability for synthesis of inflammatory eicosanoids, such as prostaglandins (By similarity). In enterocytes, acts as a component of a gut-brain feedback loop that coordinates dietary lipid absorption and food intake. Regulates the abundance of PCs containing linoleate and arachidonate in enterocyte membranes, enabling passive diffusion of fatty acids and cholesterol across the membrane for efficient chylomicron assembly (By similarity). In the intestinal crypt, acts as a component of dietary-responsive phospholipid-cholesterol axis, regulating the biosynthesis of cholesterol and its mitogenic effects on intestinal stem cells (By similarity). . |
Accessions | F5H0M4 ENST00000261407.9 [Q6P1A2-1] ENST00000536797.5 ENST00000535479.5 Q6P1A2 F5GYT3 F5H680 ENST00000538910.1 F5H7K7 ENST00000543794.5 B7Z3N5 ENST00000540090.5 |